Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02213744
Title MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab + Vinorelbine

Capecitabine + Trastuzumab

Gemcitabine + Trastuzumab

MM-302 + Trastuzumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.